α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis

BACKGROUND: The anti-α4β7 integrin antibody vedolizumab is an established therapeutic option for the treatment of inflammatory bowel disease (IBD). It has also been successfully used in patients with chronic antibiotic-refractory pouchitis following proctocolectomey with ileal pouch-anal anastomosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Melde, Michaela, Müller, Tanja M., Schneider, Ines, Geppert, Carol-Immanuel, Mühl, Laura, Besendorf, Laura, Allner, Clarissa, Becker, Emily, Atreya, Imke, Vitali, Francesco, Atreya, Raja, Neurath, Markus F., Zundler, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640978/
https://www.ncbi.nlm.nih.gov/pubmed/34868349
http://dx.doi.org/10.1177/17562848211054707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640978/
https://www.ncbi.nlm.nih.gov/pubmed/34868349
http://dx.doi.org/10.1177/17562848211054707

Ejemplares similares